Most glomerular diseases are immunologically mediated disorders of the kidney and are common causes of ESKD. In addition to supportive therapy, a wide range of immunosuppressive agents are used in the management of patients with these conditions. Immunosuppression requires a careful balance of risk and benefits, and many of these agents have a narrow therapeutic window and require close monitoring. This review describes the side effects of immunosuppressive agents used in recent randomized, controlled trials of glomerular disease, and highlights some of the key adverse events that determine the choice and prescription of these medications.
All Keywords
【저자키워드】 Glucocorticoids, Immunosuppression, ANCA, rituximab, kidney, adverse events, Glomerulonephritis, Immunosuppressive agents, tacrolimus, Membranous nephropathy, IgA nephropathy, Cyclophosphamide, mycophenolate mofetil, glomerular disease, lupus nephritis, Kidney Failure, Chronic,
【저자키워드】 Glucocorticoids, Immunosuppression, ANCA, rituximab, kidney, adverse events, Glomerulonephritis, Immunosuppressive agents, tacrolimus, Membranous nephropathy, IgA nephropathy, Cyclophosphamide, mycophenolate mofetil, glomerular disease, lupus nephritis, Kidney Failure, Chronic,